NASDAQ:TXMD
TherapeuticsMD, Inc.
TherapeuticsMD, Inc.'s revenue grew 71.6% in fiscal 2025 to $3.0M while operating margin rose to −145.3%.Summary generated from TherapeuticsMD, Inc.'s SEC filings. Latest annual report filed Apr 1, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$3.0M
Revenue growth+71.6%
Revenue, 5-yr CAGR−45.8%
Gross marginn/a
Operating margin−145.3%
Net margin−18.8%
ROICn/a
Return on equity−2.1%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+0.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 3 | 70 | 1 | 2 | 3 |
| Operating income | −80 | 1 | −9 | −6 | −4 |
| Net income | −172 | 112 | −10 | −2 | −1 |
| Free cash flow | −143 | n/a | n/a | n/a | n/a |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 12, 2026 - 8-KResults of operations and financial condition
May 12, 2026 - 10-K/AAmended annual report for the fiscal year ended Dec 31, 2025
Apr 1, 2026 - 8-KResults of operations and financial condition
Mar 30, 2026 - 10-KAnnual report for the fiscal year ended Dec 31, 2025
Mar 30, 2026 - 8-KChange in auditor
Jan 21, 2026